Economic Impact Associated with a Reduction in Surgical Eligibility among Adult Patients with Chronic Rhinosinusitis - A Population Cost Offset Model

Rationale Chronic rhinosinusitis (CRS) is a debilitating inflammatory disease generating ~$10-60B in direct costs/year in the U.S. Although maximal medical therapy (MMT) is recommended prior to surgery, it is associated with high rates of failure, and some estimates are that approximately 2% of patients progress to endoscopic sinus surgery (ESS) every year. Methods A three-year cost-offset model was developed incorporating CRS-related parameters derived from the medical literature: prevalence, ESS progression rate, revisions, post-ESS complication rate, and post-ESS healthcare costs.